Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, after the company lost its first mover ...

Danish drugmaker Novo Nordisk (NVO) announced on Thursday that it plans to initiate a late-stage development program with its experimental drug Amycretin for adults with obesity or those who are ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

The companies have said they will create customised AI models and agents that Novo Nordisk can use for early research and ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The new multiyear agreement will allow the Danish pharma to use Gefion’s computational power to “process vast datasets” with ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.